<article id="MOA_affinity" class="slide affinity" data-ag-name="MOA affinity">
  <h1>EYLEA<sup class="reg">&reg;</sup> – <br>THE ONLY ANTI-ANGIOGENIC AGENT <br>THAT BINDS BOTH VEGF AND PGF<sup class="footnote-link">2</sup><span class="asterisk">*</span></h1>
  <h2>
    <span>Mechanism of action<sup>†</sup></span>
    <span class="parallelogram"></span>    
  </h2>
  <div class="MOA_affinity">
    <h3>Molecule Design<sup>†</sup></h3>
    <div class="blue-banner">
      <p class="heading">Binding affinity vs.<br>native receptors<sup class="footnote-link">1</sup></p>
      <p>EYLEA<sup class="reg">&reg;</sup> acts as a soluble decoy receptor that binds VEGF<br>and PGF with higher affinity than their natural receptors,<br>inhibiting the activation of their cognate VEGF receptors<span class="asterisk">*</span></p>
    </div>
  </div>
  <div class="MOA_VEGF">
    <h3>Molecule Design<sup>†</sup></h3>
    <div class="blue-banner">
      <p class="heading">Binding to VEGF-A and PGF<sup class="footnote-link">1</sup></p>
      <p>VEGF-A and PGF are pro-angiogenic factors</p>
      <ul>
        <li>VEGF acts via VEGFR 1 and VEGFR 2, present on the surface<br> 
        of endothelial cells</li>
        <li>PGF binds only to VEGFR 1, present on the surface of endothelial<br> 
        cells and leukocytes</li>
        <li>Excessive activation of VEGFR 1 and VEGFR 2 by VEGF-A can<br> 
        result in neovascularization and excessive vascular permeability</li>
      </ul>
    </div>
  </div>
  <div class="affinity-link"><span>+</span><span>Binding Affinity</span></div>
  <div class="vegf-a-link"><span>+</span><span>Binding to<br>VEGF-A and PGF</span></div>
  <div class="keys">
    <div class="chart-key">VEGF=vascular endothelial growth factor; PGF=placental growth factor.</div>
    <div class="chart-key">* Comparative clinical significance has not been established.</div>
    <div class="chart-key">† Clinical significance unknown.</div>
  </div>
</div>
</article>